Last reviewed · How we verify
dexmedetomidine 0.25 µg/kg IV
dexmedetomidine 0.25 µg/kg IV is a Alpha-2 adrenergic receptor agonist Small molecule drug developed by American University of Beirut Medical Center. It is currently FDA-approved for Sedation of initially intubated and mechanically ventilated patients in intensive care settings, Procedural sedation in awake patients undergoing diagnostic or therapeutic procedures.
Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system.
Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system. Used for Sedation of initially intubated and mechanically ventilated patients in intensive care settings, Procedural sedation in awake patients undergoing diagnostic or therapeutic procedures.
At a glance
| Generic name | dexmedetomidine 0.25 µg/kg IV |
|---|---|
| Sponsor | American University of Beirut Medical Center |
| Drug class | Alpha-2 adrenergic receptor agonist |
| Target | Alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia and Sedation |
| Phase | FDA-approved |
Mechanism of action
Dexmedetomidine binds with high selectivity to alpha-2 adrenergic receptors, particularly in the locus coeruleus and other brainstem regions, leading to decreased norepinephrine release and reduced neuronal firing. This results in a unique sedative state characterized by maintained airway reflexes and the ability to be aroused, along with analgesic and anxiolytic effects. The drug is commonly used for procedural sedation and ICU sedation in mechanically ventilated patients.
Approved indications
- Sedation of initially intubated and mechanically ventilated patients in intensive care settings
- Procedural sedation in awake patients undergoing diagnostic or therapeutic procedures
Common side effects
- Hypotension
- Bradycardia
- Hypertension (transient, initial)
- Dry mouth
- Rebound hypertension on discontinuation
Key clinical trials
- Intrathecal Morphine for Recovery and Outcomes After VATS (NA)
- Efficacy of Propofol Combination With Either Ketamine, Dexmedetomidine or Midazolam for Sedation During Upper Gastrointestinal Endoscopic Procedures (PHASE4)
- Venous Cannulation Pain to Guide Choice of Anesthetic Method (NA)
- Adding Magnesium Sulfate or Dexmedetomidine to Bupivacaine in Oblique Subcostal Tap Block for Laparoscopic Cholecystectomy: a Randomized Double -Blind Controlled Study (PHASE4)
- Dexmedetomidine for Improved Pain Relief and Recovery in Spine Surgery (NA)
- Axillary Brachial Plexus Block Using 0.25% Bupivacaine Versus Using 0.19%Bupivacaine in Pediatrics (NA)
- Intravenous Dexmedetomidine For The Quaity Of Emergence From General Anesthesia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- dexmedetomidine 0.25 µg/kg IV CI brief — competitive landscape report
- dexmedetomidine 0.25 µg/kg IV updates RSS · CI watch RSS
- American University of Beirut Medical Center portfolio CI
Frequently asked questions about dexmedetomidine 0.25 µg/kg IV
What is dexmedetomidine 0.25 µg/kg IV?
How does dexmedetomidine 0.25 µg/kg IV work?
What is dexmedetomidine 0.25 µg/kg IV used for?
Who makes dexmedetomidine 0.25 µg/kg IV?
What drug class is dexmedetomidine 0.25 µg/kg IV in?
What development phase is dexmedetomidine 0.25 µg/kg IV in?
What are the side effects of dexmedetomidine 0.25 µg/kg IV?
What does dexmedetomidine 0.25 µg/kg IV target?
Related
- Drug class: All Alpha-2 adrenergic receptor agonist drugs
- Target: All drugs targeting Alpha-2 adrenergic receptor
- Manufacturer: American University of Beirut Medical Center — full pipeline
- Therapeutic area: All drugs in Anesthesia and Sedation
- Indication: Drugs for Sedation of initially intubated and mechanically ventilated patients in intensive care settings
- Indication: Drugs for Procedural sedation in awake patients undergoing diagnostic or therapeutic procedures
- Compare: dexmedetomidine 0.25 µg/kg IV vs similar drugs
- Pricing: dexmedetomidine 0.25 µg/kg IV cost, discount & access